The global alpha 1 antitrypsin deficiency treatment market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.1 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028. More Info:- https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-treatment-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Alpha 1 Antitrypsin
Deficiency Treatment Market
Research and Forecast
Report 2023-2028
Author: Elena Anderson,
Marketing Manager |
IMARC Group
© 2019 IMARC All Rights Reserved

2. Report Description
About IMARC Group
The International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all sectors
and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report:
The latest report by IMARC, titled “Alpha 1 Antitrypsin Deficiency Treatment Market: Global Industry
Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” the global alpha 1 antitrypsin
deficiency treatment market reached a value of US$ 1.9 Billion in 2022.
Alpha 1 antitrypsin deficiency (AAT) is an inherited condition wherein the body fails to produce an
adequate amount of AAT, a protein that protects the lungs and liver from the harmful effects of other
proteins. Its deficiency often leads to liver cirrhosis, emphysema diseases and chronic obstructive
pulmonary diseases (COPD).
Some of its common symptoms include tiredness, vision problems, weight loss, shortness of breath,
repeated lung infections and rapid heartbeat on standing. AAT deficiency is nowadays treated using
different therapeutic methods, such as corticosteroids, oxygen therapy, bronchodilators and
augmentation therapy.
Request Free Sample Report: https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-
treatment-market/requestsample

4. Report Description
Report Description and Highlights
Global Alpha 1 Antitrypsin Deficiency Treatment Market Trends:
The global market is presently experiencing growth on account of the rising cases of the alpha 1 antitrypsin deficiency
and the increasing prevalence of chronic respiratory diseases. Besides this, technological advancements in diagnostic
methods, along with the development of innovative processes for the production and purification of AAT, are
positively influencing the demand for the treatment. Furthermore, the increasing expenditure on research and
development (R&D) in asthma and chronic obstructive pulmonary disease (COPD) treatment, in confluence with the
growing number of awareness programs, is propelling the growth of the market.
However, the sudden spread of the coronavirus disease (COVID-19) and lockdowns imposed by governments of
numerous countries have negatively influenced the market growth on account of temporary disturbances caused in
the supply chain and operations of manufacturing units. The market is expected to experience growth once normalcy
is regained. Looking forward, the market value is projected to reach US$ 3.1 Billion by 2028, expanding at a CAGR of
8.3% during the forecast period (2023-2028).
Looking forward, the market value is projected to reach a strong growth during the forecast period
(2023-2028).

5. Report Description
Report Description and Highlights
Market Summary:
Breakup by Treatment Type:
• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy
• Others
Breakup by Route of Administration:
• Parenteral
• Inhalation
• Oral
Breakup by End User:
• Hospitals
• Specialty Clinics
• Others
Breakup by Region:

6. Report Description
Report Description and Highlights
• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America

7. Report Description
Report Description and Highlights
• Brazil
• Mexico
• Others
• Middle East and Africa

8. Competitive Landscape with Key Players:
• AstraZeneca PLC
• C.H. Boehringer Sohn AG & Ko. KG
• CSL Limited
• GlaxoSmithKline Plc
• Grifols S.A.
• Kamada Ltd.
• LFB Biomedicaments S.A.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/alpha-1-antitrypsin-
deficiency-treatment-market
Report Description
Report Description and Highlights

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us